Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Free Cash Flow (2020 - 2025)

Bioventus (BVS) has disclosed Free Cash Flow for 6 consecutive years, with $37.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 89.67% year-over-year to $37.4 million, compared with a TTM value of $72.1 million through Dec 2025, up 86.08%, and an annual FY2025 reading of $72.1 million, up 86.08% over the prior year.
  • Free Cash Flow was $37.4 million for Q4 2025 at Bioventus, up from $29.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $37.4 million in Q4 2025 and bottomed at -$24.0 million in Q2 2022.
  • Average Free Cash Flow over 5 years is $6.7 million, with a median of $9.4 million recorded in 2021.
  • The sharpest move saw Free Cash Flow surged 1372.72% in 2023, then crashed 666.24% in 2024.
  • Year by year, Free Cash Flow stood at $17.0 million in 2021, then tumbled by 31.28% to $11.7 million in 2022, then dropped by 29.79% to $8.2 million in 2023, then skyrocketed by 140.45% to $19.7 million in 2024, then skyrocketed by 89.67% to $37.4 million in 2025.
  • Business Quant data shows Free Cash Flow for BVS at $37.4 million in Q4 2025, $29.6 million in Q3 2025, and $25.3 million in Q2 2025.